The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...